SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-010937
Filing Date
2021-05-05
Accepted
2021-05-05 17:05:20
Documents
2
Period of Report
2021-05-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20210505_8k.htm 8-K 24979
2 EXHIBIT 99.1 ex_246990.htm EX-99.1 10690
  Complete submission text file 0001437749-21-010937.txt   37013
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 21894414
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences